
A study analyzed the effectiveness of treatment after discontinuing immune checkpoint inhibitors (ICI) in patients with squamous cell carcinoma. Out of 99 cases studied, 79 had discontinued ICI. After discontinuation, 40 cases received active treatment with salvage chemotherapy or surgery/radiotherapy, while 39 cases received nonactive treatment. Active treatment showed a significant increase in overall survival compared to nonactive treatment. Among salvage chemotherapy regimens, paclitaxel and cetuximab (PTX-Cmab) demonstrated a trend towards increased survival. The study suggests that active treatment after ICI discontinuation and PTX-Cmab may improve head and neck squamous cell carcinoma outcomes.
Like
Save
Share